Intraday Movers: Air Products & Chemicals, Inc. (NYSE:APD), LinkedIn Corp (NYSE:LNKD), Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

On Monday, Shares of Air Products & Chemicals, Inc. (NYSE:APD), subtract -6.59% and closed at $140.57 in the last trading session. The last trading range of the stock ranges between $138.85 and $141.02. Air Products (APD) has named Sea-Land Chemical Company as Central United States distributor for several of the company’s Functional Additives offerings which include Tomadol®, Tomamine®, Nonidet®, Tomakleen™, Tomadry™ and Tomadyne™ products. Effective November 1, 2016, Sea-Land will replace Harcros Chemicals, Inc. as Air Products’ distributor in Minnesota, Iowa, Missouri, Kansas, Colorado, Nebraska, Montana, South Dakota and North Dakota.

Sea-Land presently distributes these product lines for Air Products Functional Additives offerings in the Midwest and Southeast regions of the U.S.  The line of products are used as surfactants in various markets counting Industrial & Institutional Cleaning and Metalworking.

Sea-Land Chemical Company has over 50 years of experience offering specialty chemicals around the globe.  Sea-Land’s sales team has extensive technical knowledge of these product lines and their applications, and have demonstrated success in assisting industry formulators fulfill their performance and cost targets with these products.

LinkedIn Corp (NYSE:LNKD), jumped 0.43% and closed at $191.95 in the last trading session. The last trading range of the stock ranges between $191.15 and $192.13. The company’s Market capitalization is $25.90 Billion with the total Outstanding Shares of 119.16 million. LinkedIn Corporation, together with its auxiliaries, operates an online professional network worldwide. The company, through its proprietary platform, allows members to create, manage, and share their professional identity online; build and engage with their professional networks; access shared knowledge and insights; and find business opportunities. It also offers LinkedIn mobile applications across a range of platforms and languages, counting iOS for iPhone and iPad, Android, Blackberry, Nokia Asha, and Windows Mobile; and a public Website that allows developers to integrate its content and services into their applications. In addition, the company provides talent solutions, counting hiring solutions that facilitate enterprises and professional organizations to find, contact, and hire qualified passive and active candidates; and learning and development solutions, which provide online education courses to make it for professionals to accelerate their careers and realize their potential by learning new skills. Further, it offers marketing solutions products that facilitate enterprises and individuals the ability to advertise to its member base; and allow marketers to reach potential customers according to various attributes, such as industry, function, seniority, company size, and others. In Addition To, the company provides premium subscription services that are designed for general professionals to manage their professional identity, grow their networks, and connect with talent; LinkedIn Sales Navigator, a social selling solution that provides sales professionals with the ability to find, qualify, and create new opportunities and assists sales administration; and LinkedIn Profinder, a platform that connects members to top freelance professionals in their area.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), gained 0.76% and closed at $16.00 in the last trading session. The last trading range of the stock ranges between $15.49 and $16.03. During the 52-week trading session the minimum price at which share price traded, registered at $7.35 and reached to max level of $6.17. A new survey conducted among primary care physicians and rheumatologists found that despite their overall agreement that gout is a serious and chronic medical condition with potential long-term consequences, patients remain at risk. Of physicians surveyed, 89 percent agree that achieving serum uric acid (sUA) levels <6 mg/dL is imperative, yet only 51 percent report their patients with gout are reaching this target.

Further, nearly all (94 percent) of healthcare providers (HCPs) surveyed indicate that gout needs to be treated aggressively given long-term consequences, but express frustration (82 percent) when treatments fail to control sUA levels. A majority (89 percent) of physicians surveyed express a desire for additional treatment options for their patients.

“What I find most concerning about these findings is that we as physicians agree gout is not only a painful, often debilitating disease, but can have long-term consequences like permanent joint damage. Moreover, studies are showing a good deal of association between gout and comorbid conditions such as cardiovascular disease and kidney disease. Yet clinicians who treat patients with gout are only getting about half of those patients to their target sUA levels,” said Paul Doghramji, M.D., Family Physician, Collegeville Family Practice, Collegeville, PA. “I think there are two reasons why: we haven’t had enough treatment options to assist manage the disease and there are continued misconceptions about gout that contribute to ineffective disease administration.”


Leave a Reply

Your email address will not be published. Required fields are marked *